Search results | asset purchase

Reports

Asset Purchase Terms and Agreements in Pharma, Biotech and Diagnostics

The Asset Purchase Terms and Agreements in Pharma, Biotech and Diagnostics report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty asset purchase deals.

Insights

Asset purchase deal trends among life sciences companies

An asset purchase agreement is an agreement between a buyer and a seller that finalizes terms and conditions related to the purchase and sale of life sciences company’s assets.

Asset purchase

An asset purchase is an agreement between a buyer and a seller that finalizes terms…

Aspen proposed big pharma deals with GlaxoSmithKline for Arixtra and Fraxiparine asset purchase

GlaxoSmithKline, a big pharma company, is discussing pharma deals for the sale of its thrombosis drug brands Arixtra and Fraxiparine, along with a related French factory, to Aspen Pharmacare in a deal that could be worth some $1 billion.

Dealtalk: Abbott plans to acquire Johnson & Johnson assets

According to dealtalk, Abbott Laboratories is presently evaluating an asset purchase transaction, whereby, it may acquire certain assets of Johnson & Johnson in Pakistan.

Watson sets aside $6 billion to buy brand-name drug assets

Watson‘s Chief Executive Officer Paul Bisaro is looking to acquire brand-name drug assets and make a future “‘transformational” purchase as he reshapes the generic-drug maker.

Gruenenthal CEO has $1.3 billion for Latin America purchases

Gruenenthal GmbH is ready to spend 1 billion euros ($1.3 billion) on acquisitions “in the near future” to expand its pain medicines business in Latin America, Chief Executive Officer Harald Stock said.

End of year sales at GSK see disposal of non core assets

During the final weeks of 2011, GSK announced two separate disposals of non core assets as the company seeks to delist several of its OTC/consumer brands

Gilead increased bid 37% as rivals demurred on Pharmasset

Written by Ryan Flynn. Gilead Sciences Inc. increased an offer to buy experimental hepatitis C drugmaker Pharmasset Inc several times before agreeing to pay $10.8 billion, as other potential buyers bowed out before making a bid, filings show.

Forest looking at earlier assets for drug pipeline, next decade of business

With its battle for board control with billionaire Carl Icahn over (at least for this year), Forest Laboratories has its eyes on ensuring that its pipeline of experimental meds positions it for success, company CFO Frank Perier told Reuters.

The rise of the asset auction

Recent days have seen a number of announcements of pending auctions of IP in what is becoming a trend in the biopharma sector.

Events

Sorry, your search returned no results.


Deals

Pfizer in asset purchase and option to acquire AM-Pharma

Pfizer has acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the remaining equity in the company.

AstraZeneca enters asset purchase deal for branded respiratory portfolio

AstraZeneca and Actavis have entered into a definitive asset purchase agreement under which AstraZeneca will acquire the rights to Actavis’ branded respiratory business in the US and Canada for an initial consideration of

Asset purchase agreement for Mylan

Mylan has, through its Indian subsidiary Mylan Laboratories Limited, signed a definitive agreement to acquire certain female health care businesses from Famy Care Limited, a specialty women’s health care company with global leadership in generic oral contraceptive products for $750 million in cash plus additional contingent payments of up to $50 million.

Asset purchase agreement for stem cell reagent and services business unit

Stemgent has completed the sale of its stem cell reagents and services business to ReproCELL in a cash transaction for approximately $8.5 million.

Asset purchase agreement for dermatology product portfolio

Valeant Canada has completed the acquisition of Valeo Pharma’s dermatology product portfolio and several specialty products.

Asset purchase agreement for topical antibiotics and pain products

Actavis has entered into agreements with Akorn and Hi-Tech Pharmacal to purchase four currently marketed products and one product under development for cash consideration.

Boston Scientific life science deals for C R Bard electrophysiology business in $275 million asset purchase

Boston Scientific has entered life science deals in a definitive agreement to acquire Bard EP, the electrophysiology business of C.R. Bard, for $275 million in cash.

Aspen big pharma deals Merck for API business in $1 billion asset purchase

Aspen has entered big pharma deals with Merck and Co for an asset purchase agreement in which Aspen will by Merck’s API business.

MicroPort life science deals Wright Medical for $290 million OrthoRecon business in an asset purchase

Wright Medical Group announced definitive life science deals under which MicroPort Medical, will acquire Wright’s OrthoRecon business in an asset purchase.

UCB secures partnership with UNITHER Pharma in asset purchase pharma deals pact

UCB, a big pharma/ big biotech company has agreed with UNITHER Pharmaceuticals, a leading pharmaceutical manufacturer, that UNITHER will acquire UCB’s manufacturing plant in Rochester, New York in an asset purchase pharma deals pact